Live Breaking News & Updates on Military Medical Science Press

Stay updated with breaking news from Military medical science press. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chinese Military Scientists Discussed Man-Made Coronavirus Attack Years Before COVID-19 Pandemic


Chinese Military Scientists Discussed Man-Made Coronavirus Attack Years Before COVID-19 Pandemic
Chinese military scientists in 2015 detailed a plot to unleash a bioengineered SARScoronavirus to cause mass terror and advance the communist regime’s global political ambitions.
These newly uncovered revelations come amid intensifying scrutiny over the possibility that the COVID-19 pandemic originated from a laboratory leak in Wuhan, an institute that has collaborated with the Chinese military.
The Chinese military scientists’ theories were detailed in a 2015 book, first reported recently by News Corp’s The Australian. The scientists advocated for the weaponization of pathogens, including SARS coronaviruses, to “cause terror and gain political and strategic advantage” over an enemy state. ....

United States , United Kingdom , David Asher , Anders Corr , Xu Dezhong , World Health Organization , China Air Force Medical University , Fourth Military Medical University , Chinese Military Commission , Chinese Communist Party , People Liberation Army , News Corp , Us State Department , Logistics Department , Wuhan Institute Of Virology , Unnatural Origin , Genetic Weapons Based , Man Made Viruses , Military Medical Science Press , Liberation Army , Air Force Medical , Wuhan Institute , State Department , New York Based , Corr Analytics , Epoch Times ,

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia


APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed ....

Hong Kong , Remy Bernarda , Jamie Lacey Moreira , Shari Annes , Guo Liang Yu , Yang Xiaofeng , Zhang Sufen , Zhang Qingyuan , Kelly Fung , Wilsonw Cheung , Porda Havas International Finance Communications Group , Asia Corporate News Network , Drug Administration , Exchange Commission , National Cancer Institute Surveillance , China National Medical Products Administration , Glycomimetics Inc , Corporate Communications , Apollomics Inc , Granted Breakthrough Therapy Designation , Acute Myeloid , Breakthrough Therapy Designation , Drug Evaluation , Chief Executive , Investigational New Drug , Drug Registration Regulation ,